World’s first malaria vaccine soon -Governance Now

World’s first malaria vaccine soon

About 95 percent of the Indian population resides in malaria-endemic areas

Shreerupa Mitra-Jha | November 19, 2016 | Geneva

#Africa #India #WHO #vaccine #Malaria

The world’s first malaria vaccine will be rolled out in pilot settings in 2018, the results of which would give an indication of whether they can be deployed on a wider scale, the World Health Organisation confirmed on Friday.

The first-generation vaccine known as RTS, S will be tried in pilot projects in sub-Saharan Africa in 2018. Also known as Mosquirix, it works against P. falciparum, the most deadly malaria parasite globally, and has been in development for the past three decades. Until now, vaccines fought viruses and bacteria but this is the first vaccine of its kind to fight parasites targeting the T-cells, which are part of the body’s immune system.

“The pilot deployment of this first-generation vaccine marks a milestone in the fight against malaria,” said Dr. Pedro Alonso, Director of the WHO Global Malaria Programme, said in a statement.

WHO estimates that India takes the disproportionate burden for the vector-borne disease accounting for 75 percent of all malaria cases in South-East Asia. About 95 percent of the Indian population resides in malaria-endemic areas. However, 80 percent of the disease is concentrated in areas where 20 percent of the population resides in tribal and hard-to-reach or inaccessible areas—typically rural areas of eastern and north-eastern states.

Three of the world’s biggest health financing institutions—Gavi: the Vaccine Alliance, the Global Fund to Fight AIDS, Tuberculosis and Malaria and UNITAID—came together to tackle a disease that killed 4,38,000 people, largely children, in 2015.

While the Global Fund yesterday approved $15 million for the malaria vaccine pilots, Gavi and UNITAID had earlier in the year announced commitments of up to $27.5 million and $9.6 million, respectively, for the first four years of the vaccine programme.

RTS,S that has been developed by British drugmaker GlaxoSmithKline is, however, only partially effective and will only be deployed on a pilot basis before a call on its wide-scale use is taken.

It is the only vaccine to have successfully completed the important Phase 3 clinical trials, involving 15,000 infants and young children in seven countries in sub-Saharan Africa.

However, with the older children (between five and 17 months of age) who participated in the clinical trials, there was a risk of febrile seizures within a week after any one of the four doses of the vaccine while with infants, these seizures were apparent only after the fourth dose. WHO says that there were “no long-lasting consequences due to any of the febrile seizures”.

Also, during the Phase 3 RTS,S trials, meningitis and cerebral malaria cases increased among the older children who received the malaria vaccine as compared to the control group. However, no such increase was observed in infants aged 6–12 weeks. The significance of these findings in relation to the vaccination is unclear, the UN’s health agency says.

Mosquirix, created as a partnership between GSK and the PATH Malaria Vaccine Initiative (MVI), needed an investment of more than $565 million of which Bill and Melinda Gates Foundation have contributed more than $200 million while African research centres contributed the rest.

The vaccine was approved by the European Medicines Agency in July last year paving the way for WHO to adopt the SAGE-MPAC recommendations at the beginning of the year of a pilot implementation of the RTS,S vaccine in three to five settings in sub-Saharan Africa.

“These pilots are critical to determine whether this vaccine can be rolled out more broadly, adding an important new tool to the proven interventions we already have in the fight against malaria,” Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance said.

Comments

Other News

`Climate change weakens La Nina’s cooling effect, triggers early heatwaves across India`

India is witnessing an unusually early onset of summer this year, with winter ending by early February and heatwave conditions already emerging across several parts of the country. Scientists say the trend reflects how long-term climate change is increasingly overpowering natural climate patterns such as L

`BMC school enrolment rises to 44%, only 48% students reach class 10`

Student enrolment in schools run by the Brihanmumbai Municipal Corporation (BMC) has seen a gradual rise over the past decade, reaching 44% in 2024–25, according to the latest report released by the Praja Foundation. However, the report highlights significant concerns over student retention, language

Will AI usher in a new agricultural revolution?

The 2026 Union Budget highlights the necessity of making scientific agricultural research more accessible to farmers in India. The announcement of Bharat- VISTAAR (Virtually Integrated System to Access Agricultural Resources), a multilingual AI tool for farmers to increase agricultural productivity, indica

Freedom of speech in Parliament is guaranteed: Lok Sabha speaker

Lok Sabha speaker Om Birla on Thursday emphasized that freedom of speech in Parliament is guaranteed, but it is subject to the Constitution and to the rules and standing orders regulating the procedure of Parliament. He said that detailed guidelines exist under the rules regarding how Members should conduc

Beyond broken bones: The bruises the law cannot see

When violence becomes lawful in one place and tolerable everywhere else, the bruises are no longer Afghanistan’s alone; they belong to all of us. Somewhere a woman walks in silence, Counting the bruises no one will see. The la

Jishnu Dev Varma sworn in as governor of Maharashtra

Jishnu Dev Varma was sworn in as the 22nd Governor of Maharashtra on Tuesday at a ceremony held at the Durbar Hall of Raj Bhavan. The oath of office was administered by Chandrashekhar, Chief Justice of the Bombay High Court. The ceremony commenced with the national anthem and t